Astrid A.M. van der Veldt

Author

Also Known As

A A M van der Veldt, A. A. M. Van Der Veldt, A. A. M. van der Veldt, A.A.M. Van der Veldt, A.A.M. Veldt, A.A.M. van der Veldt, Astrid A M Van der Veldt, Astrid A M van der Veldt, Astrid A. M. Van der Veldt, Astrid A. M. van der Veldt

359

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute University Medical Center Groningen Radboud University Medical Center Radboud University Nijmegen Erasmus MC Cancer Institute

About

Astrid A.M. van der Veldt is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	29	1.4K
2	Health Sciences	7	7	140
3	Public Health	2	2	162
4	Cell Biology	1	1	50
5	Epidemiology	1	1	77

Astrid A.M. van der Veldt

100

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, New England Journal of Medicine	2022	474
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs Astrid A.M. van der Veldt, Mark Lubberink, Idris Bahce, Cancer Cell	2012	333
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi, Nature Medicine Surgical OncologyOncologyPrado TrialMelanomaClinical Trials	2022	322
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective Karlijn de Joode, Daphne W. Dumoulin, Vivian Engelen, European Journal of Cancer Coronavirus Disease 2019Virus EpidemiologyCovid-19 PandemicVirologyCovid-19 Epidemiology	2020	179
Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response Astrid A.M. van der Veldt, Martijn R. Meijerink, Alfons J.M. van den Eertwegh, Clinical Cancer Research	2008	170
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib Astrid A.M. van der Veldt, Karel Eechoute, Hans Gelderblom, Clinical Cancer Research	2010	156
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib Astrid A.M. van der Veldt, Martijn R. Meijerink, Alfons J.M. van den Eertwegh, British Journal of Cancer	2010	150
Women with silicone breast implants and unexplained systemic symptoms: a descriptive cohort study. Maria C. Maijers, Christel J.M. de Blok, Frank B. Niessen, PubMed	2013	142
Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival Hester van Cruijsen, Astrid A.M. van der Veldt, Laura Vroling, Clinical Cancer Research	2008	132
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer Astrid A.M. van der Veldt, Epie Boven, Helgi H. Helgason, British Journal of Cancer	2008	130

Page 1